Q2 Earnings Estimate for TWST Issued By Leerink Partnrs

Twist Bioscience Co. (NASDAQ:TWST) – Analysts at Leerink Partnrs increased their Q2 2025 EPS estimates for Twist Bioscience in a research note issued to investors on Monday, February 3rd. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings of ($0.59) per share for the quarter, up from their prior forecast of ($0.62). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.27) per share. Leerink Partnrs also issued estimates for Twist Bioscience’s Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($2.18) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.77) EPS.

Several other research firms have also recently weighed in on TWST. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Wolfe Research started coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Barclays reduced their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. Robert W. Baird increased their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Scotiabank boosted their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.80.

Twist Bioscience Trading Up 3.2 %

Twist Bioscience stock opened at $53.66 on Thursday. The company has a 50-day moving average price of $48.74 and a 200 day moving average price of $46.27. Twist Bioscience has a 12-month low of $27.41 and a 12-month high of $60.90. The stock has a market cap of $3.19 billion, a P/E ratio of -14.91 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter last year, the firm earned ($0.75) earnings per share. The business’s revenue for the quarter was up 24.1% on a year-over-year basis.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 7,968 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $382,464.00. Following the completion of the transaction, the chief executive officer now directly owns 581,584 shares of the company’s stock, valued at $27,916,032. The trade was a 1.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Paula Green sold 860 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $52.70, for a total value of $45,322.00. Following the sale, the senior vice president now owns 133,715 shares in the company, valued at approximately $7,046,780.50. This trade represents a 0.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,002 shares of company stock valued at $2,851,681 in the last three months. 3.01% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC grew its holdings in Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after acquiring an additional 237,772 shares in the last quarter. State Street Corp lifted its position in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Twist Bioscience by 1.9% during the third quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after purchasing an additional 26,145 shares in the last quarter. Thrivent Financial for Lutherans purchased a new position in Twist Bioscience in the third quarter valued at $43,992,000. Finally, Wellington Management Group LLP raised its stake in Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after buying an additional 521,272 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.